Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT011 in HCC at Risk of Recurrence
NCT06560827Phase 1Recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT011 in hepatocellular carcinoma (HCC), sponsored by CARsgen Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events up to 12 months, Treatment-Related Adverse Events up to 12 months and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
CT011
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06560827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560827.